# Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus

> **NCT02554019** · PHASE2 · COMPLETED · sponsor: **Biotest** · enrollment: 36 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** BT063
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02554019
- **Lead sponsor:** Biotest
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-28
- **Primary completion:** 2017-10-25
- **Final completion:** 2017-10-25
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02554019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02554019, "Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02554019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*